Jan Tesarik

Dr. Jan Tesarik


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Jan TesarikJan Tesarik
Jan Tesarik
MGMaribel Galán-Lázaro
Maribel Galán-Lázaro
JTJan Tesarik
Jan Tesarik
This is a short review of the basic molecular mechanisms of ovarian aging, written with a particular focus on the use of this data to improve the diagnostic and therapeutic protocols both for women affected by physiological (age-related) ovarian decay and for those suffering premature ovarian insufficiency. Ovarian aging has a genetic basis that conditions the ovarian activity via a plethora of cell-signaling pathways that control the functions of different types of cells in the ovary. There are various factors that can influence these pathways so as to reduce their efficiency. Oxidative stress, often related to mitochondrial dysfunction, leading to the apoptosis of ovarian cells, can be at the origin of vicious circles in which the primary cause feeds back other abnormalities, resulting in an overall decline in the ovarian activity and in the quantity and quality of oocytes. The correct diagnosis of the molecular mechanisms involved in ovarian aging can serve to design treatment strategies that can slow down ovarian decay and increase the quantity and quality of oocytes that can be obtained for an in vitro fertilization attempt. The available treatment options include the use of antioxidants, melatonin, growth hormones, and mitochondrial therapies. All of these treatments have to be considered in the context of each couple’s history and current clinical condition, and a customized (patient-tailored) treatment protocol is to be elaborated.

Verified
Journal Article
Open access
PDF file
Jan TesarikJan Tesarik
Jan Tesarik
JTJan Tesarik
Jan Tesarik
In human spermatozoa and oocytes (and their surrounding granulosa cells), mitochondria carry out important functions relating to human fertility and infertility. Sperm mitochondria are not transmitted to the future embryo, but are closely related to the generation of energy needed for sperm movement, capacitation, and acrosome reactions, as well as for sperm–oocyte fusion. On the other hand, oocyte mitochondria produce energy required for oocyte meiotic division and their abnormalities can thus cause oocyte and embryo aneuploidy. In addition, they play a role in oocyte calcium metabolism and in essential epigenetic events during the oocyte-to-embryo transition. They are transmitted to the future embryos and may thus cause hereditary diseases in the offspring. Due to the long life span of the female germ cells, the accumulation of mitochondrial DNA abnormalities often causes ovarian aging. Mitochondrial substitution therapy is the only way of dealing with these issues nowadays. New therapies based on mitochondrial DNA editing are under investigation.

6 October 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
Jan TesarikJan Tesarik
Jan Tesarik
JTJan Tesarik
Jan Tesarik
Many experimental and clinical studies published so far demonstrate that melatonin—produced mainly by the pineal gland located deep in the middle of the brain, between the two cerebral hemispheres, and in smaller quantities in a number of other organs and cells of the body—can be successfully used to treat different types of human female infertility. To accomplish this, melatonin acts mainly on the ovary, the uterus, and the preimplantation embryo, through its antioxidant, anti-inflammatory, and immunomodulatory effects, in addition to acting as a hormone and cytokine modulator. In particular, it increases oocyte developmental competence and uterine receptivity for the implanting embryo, improves placental health and function, prevents immune rejection of the implanting embryo and spontaneous pregnancy loss, and alleviates symptoms of endometriosis and adenomyosis. Yet, the use of melatonin in these contexts remains relatively limited, despite its convincing safety profile. This may be partly due to the fact that pertinent data concerning the use of melatonin in female infertility treatment are dispersed across various specialized scientific and medical journals, making it difficult for doctors and embryologists confronted with female infertility issues to access all of them. Therefore, this article was written to provide data that are easily understood. It draws from recent findings collected from different specialized journals focused on the molecular mechanisms of action, the clinical data, and the safety of this multifaceted biomolecule in the treatment of female infertility.

Verified
Journal Article
Open access
PDF file
Jan TesarikJan Tesarik
Jan Tesarik
JTJan Tesarik
Jan Tesarik
Ovarian aging (OA) results from the senescence of different cell types present in the ovary, decreasing female fertility and quality of life and augmenting the risk of a variety of fertility-unrelated pathological conditions. The changes observed in the ovarian cells are accompanied by changes occurring in various elements of the hypothalamic–pituitary–ovarian (HPO) axis, the complex endocrine system that regulates the female reproductive cycle. Issues pertaining to the HPO axis have been addressed in animal models via hormonal treatments with preparations inhibiting ovarian follicular recruitment at the level of the receptors of gonadotropin-releasing hormone (GnRH)-secreting neurons, mainly acting on glutamate- and gamma-aminobutyric acid (GABA)-driven signaling. GnRH agonists and antagonists have also been used in women exposed to chemotherapeutics. HPO-independent OA can be delayed through the administration of different antioxidants and mitochondria-protecting agents, among which melatonin has been shown to be particularly useful. Other therapeutic approaches used with success in women include hormonal and growth factor (GF) modulators, such as growth hormone (GH), insulin-like growth factor 1 (IGF-1), vascular endothelial growth factors (VEGF), and dehydroepiandrosterone (DHEA), and the development of patient-tailored combination-based therapies (IGF-1 + VEGF + DHEA) has also been suggested. Intraovarian injection of autologous platelet-rich plasma (PRP), mitochondrial donation through pronuclear transfer, and ovarian tissue cryopreservation and autotransplantation have also yielded promising results in women, and their use can preserve not only fertility but also the ovarian endocrine function. Personalized mixtures of specific agents (desatinib, quercetin, rapamycin, metformin, resveratrol, melatonin, and coenzyme Q10) targeting different cell types in the ovary are currently under investigation. Overall, this review aims to present a global view of the subject, uniting the physiological and molecular background of this pathology with the history and development of potential treatment strategies and new perspectives in this domain. As such, this study may be helpful both to clinicians facing problems resulting from OA and to researchers pursuing further developments in this field.

29 May 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
JTJan Tesarik
Jan Tesarik
RTRaquel Mendoza Tesarik
Raquel Mendoza Tesarik
Apart from the male genome, the fertilizing spermatozoon delivers to the oocyte several factors that are needed for embryonic development and whose deficiency can cause human embryo dysfunction. Sperm oocyte-activating factor, identified as phoshoplipase C zeta (PLCζ), drives oocyte exit from meiotic arrest and preparation for the first mitotic division by a signaling pathway initiated by periodic rises of free cytosolic Ca2+ concentration (calcium oscillations). Sperm centrioles together with oocyte proteins form centrosomes that are responsible for aster formation, pronuclear migration and DNA polarization before nuclear syngamy and subsequent mitotic divisions. Sperm DNA fragmentation can be at the origin of aneuploidies arising from mistakes of zygote mechanisms of DNA repair, while epigenetic issues, mainly abnormal methylation of DNA-associated histones, causes asynchronies of zygotic gene activation among embryonic cells. Sperm long and short noncoding RNAs, mainly, microRNAs, are important epigenetic regulators affecting genes involved in critical developmental processes. Dysfunction of sperm PLCζ, centrioles, DNA and RNA converge to serious impediments of embryo development which ultimately result in aneuploidy, developmental arrest or implantation failure, when manifested early in embryo development, but they may also emerge after implantation and cause miscarriage, abortion or offspring disease. With the exception of DNA fragmentation, the other sperm issues are more difficult to diagnose. Specific tests, including heterologous human intracytoplasmic sperm injection (ICSI) into animal oocytes, genetic testing for mutations in PLCZ1 (the gene coding for PLCζ in humans) and associated genes, and next-generation sequencing of sperm DNA and RNA and currently available. Customized treatment of sperm DNA damage and in vitro selection of healthy spermatozoa can be used in cases of sperm DNA fragmentation, while ICSI with assisted oocyte activation is useful to overcome oocyte-activation defects. No specific and clinically confirmed treatments for problems derived from sperm centrioles, DNA (except fragmentation) and RNA are available yet.

25 August 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
Jan TesarikJan Tesarik
Jan Tesarik
JTJan Tesarik
Jan Tesarik
Many experimental and clinical studies published so far demonstrate that melatonin can be used with success in the treatment of different types of human female infertility, improving oocyte developmental competence and uterine receptivity for the implanting embro, preventing immune rejection of the implanting embryo and spontaneous pregnancy loss, and alleviating symptoms of endometriosis and adenomyosis. Yet, the use of melatonin in these indications still remains relatively limited, despite its convincing safety profile. This may be partly due to the fact that pertinent data are dispersed among different publication supports and thus do not easily reach the doctors treating female infertility issues. This review focuses on recent data concerning molecular mechanisms of action, clinical data and safety of this multifaceted biomolecule in the treatment of female infertility.